NovaBridge Biosciences has filed an amendment to its Schedule 13D, revealing important updates regarding its shareholder structure. The filing, submitted on November 5, 2026, indicates that HHLR Advisors and Hillhouse Investment Management collectively hold a significant stake in the company. This development is particularly relevant as it underscores the ongoing consolidation in the pharmaceutical preparations industry.

NovaBridge Biosciences, traded under the ticker NBP on the Nasdaq, is categorized under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company, previously known as I-Mab, has been actively involved in the life sciences sector, focusing on innovative therapeutics. The recent filing is part of a series of amendments that provide insights into the company's evolving shareholder landscape.

The Schedule 13D/A filing highlights that HHLR Advisors and Hillhouse Investment Management collectively own approximately 13,295,306 ordinary shares, representing about 4.9% of the total outstanding shares. This amendment marks the sixth update to the original Schedule 13D filed in September 2020. Notably, the filing states, "This Amendment No. 6 is the final amendment to the Schedule 13D and constitutes an 'exit filing' for each of the Reporting Persons." This indicates a potential shift in the investment strategy of these firms regarding their holdings in NovaBridge.

The filing also provides transaction details in the ordinary shares over the past 60 days, revealing that on November 5, 2026, HHLR Advisors sold 200,000 American Depositary Shares (ADSs) at a price of $1.01 per ADS. This transaction is significant as it reflects the active management of their investment portfolio and could influence market perceptions of NovaBridge's stock.

As NovaBridge continues to navigate the competitive landscape of pharmaceutical preparations, the involvement of major investment firms like HHLR and Hillhouse may impact its strategic direction and market positioning. The filing suggests that these firms are closely monitoring their investments and may adjust their strategies based on market conditions and company performance.

Moving forward, it remains to be seen how this updated shareholder information will affect NovaBridge's operations and its standing within the pharmaceutical industry. The filing does not specify what actions will follow this amendment, leaving stakeholders to speculate on the potential implications for the company's future.